It’s estimated there are 193 million asthma sufferers worldwide, but a new study reports some may find relief in an anti-fungal treatment.
Researchers in Manchester found oral anti-fungal drugs significantly improved asthma symptoms and control in sufferers who also have a condition known as allergic bronchopulmonary aspergillosis (ABPA). ABPA is a response from the immune system that causes inflammation lungs airways.
The drug used in the study, itraconazole, had a 60% response rate. The study suggests that more community-based studies of asthma and ABPA should be conducted.Read more at University of Manchester